News | Radiation Oncology | July 21, 2021

Mercy St. Louis Begins Installation of Mevion Proton Therapy System

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

The 15-ton compact accelerator is lifted into the David C. Pratt Cancer Center at Mercy St. Louis. (Photo: Business Wire)

July 23, 2021 — Mevion Medical Systems announced that it has delivered the 15-ton compact accelerator to Mercy Hospital St. Louis in Missouri. The accelerator, the world’s smallest, is the core of the MEVION S250i Proton Therapy System which precisely delivers therapeutic doses of radiation to tumors while preserving healthy tissue and critical organs.

The arrival of the accelerator commences the installation of the proton system at the David C. Pratt Cancer Center at Mercy St. Louis. The nationally accredited center provides outpatient treatment, radiation oncology and infusion services for patients throughout the Mercy network. Mevion’s unique and compact design enabled the new proton center to be embedded directly into the existing radiation oncology department. This efficient approach allows the hospital to share existing resources and offer patients all its cancer-fighting tools under one roof.

“This major milestone in construction puts us one step closer to making the Mercy Proton Therapy Center a reality for our patients,” said Steve Mackin, Mercy executive vice president and Mercy’s East Communities president. “Seeing the equipment before it’s enclosed in the concrete vault shows just how massive an undertaking this project has been. It’s remarkable to think of the many people who will survive – and thrive – because of this technology.”

The MEVION S250i features the industry-leading HYPERSCAN pencil beam scanning technology and Adaptive Aperture pMLC, a powerful duo that provides faster and more precise dose delivery, Mevion’s natively integrated CBCT imaging, and surface-guided tracking from C-RAD for high precision patient positioning and intra-fraction motion management.

“We are proud to partner with Mercy to provide this leading-edge technology,” said Tina Yu, Ph.D., CEO of Mevion Medical Systems. “Mevion’s mission is to make proton therapy accessible and the quality and value of the MEVION S250i has enabled more centers, like Mercy, to provide this powerful treatment modality to their patients.”

Reducing the size and complexity of a proton therapy system has allowed more hospitals to adopt proton therapy without the enormous expenditures and space requirements of other proton systems. Today, new proton therapy centers in the United States are almost exclusively compact single-room systems, and Mevion is the preferred compact room provider of NCI-Designated Cancer Centers. To date, over 6,000 patients have been treated on Mevion proton therapy systems, more than on any other compact system.

For more information:

Related Content

Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...
Cedars-Sinai Cancer researchers have discovered that intestinal microorganisms help regulate anti-tumor immune responses to radiation treatments.

Getty Images

News | Radiation Therapy | September 01, 2021
September 1, 2021 — The study, published on Aug.